What is the appropriate dosing regimen for eltrombopag in adult and pediatric patients with immune thrombocytopenia, including adjustments for hepatic impairment and aplastic anemia?

Eltrombopag Dosing

For adult patients with immune thrombocytopenia, start eltrombopag at 50 mg once daily (36 mg for the specific formulation discussed), adjusting by 25 mg increments every 2 weeks to maintain platelets ≥50 × 10⁹/L, with a maximum dose of 75 mg daily; for pediatric patients ≥6 years, use 50 mg daily (ages 6+) or 25 mg daily (ages 1-5), never exceeding 75 mg/day. 1

Initial Dosing by Indication

Persistent or Chronic ITP

Adults and pediatric patients ≥6 years:

• Standard starting dose: 50 mg once daily (or 36 mg for certain formulations) 1
• Reduce to 25 mg once daily for:
  • Hepatic impairment (Child-Pugh Class A, B, or C) 1
  • East/Southeast-Asian ancestry 1
  • Both conditions present simultaneously

Pediatric patients 1-5 years:

• Starting dose: 25 mg once daily 2
• Must be able to swallow tablets whole 1

Chronic Hepatitis C-Associated Thrombocytopenia

• All patients: 18 mg once daily initially 1
• Titrate to achieve platelet count needed for antiviral therapy initiation
• Maximum: 72 mg daily 1
• No dose reduction needed for hepatic impairment or Asian ancestry in this indication 1

Severe Aplastic Anemia

Adults:

• Standard: 50 mg once daily (or 36 mg for certain formulations) 1
• Reduce to 25 mg for hepatic impairment or East/Southeast-Asian ancestry 1
• Maximum: 150 mg daily 1

Pediatric patients (ages 1 to <18 years):

• Ages 6-18: 50 mg once daily 3
• Ages 1-6: 25 mg once daily 3
• Maximum: 150 mg daily 3

Dose Titration Algorithm

Adjust dose every 2 weeks based on platelet response:

1. If platelets <50 × 10⁹/L after 2 weeks: Increase by 25 mg daily 1
2. If platelets 50-150 × 10⁹/L: Continue current dose
3. If platelets >150 × 10⁹/L: Reduce by 25 mg daily 1
4. If platelets >400 × 10⁹/L: Hold dose until <150 × 10⁹/L, then restart at 25 mg lower 1

Target platelet count: ≥50 × 10⁹/L to reduce bleeding risk 2

Hepatic Impairment Dosing

The FDA label mandates dose reduction for ITP and aplastic anemia patients with any degree of hepatic impairment 1. A pharmacokinetic study demonstrated that compared to healthy participants, those with mild, moderate, or severe hepatic impairment had mean AUC increases of 41%, 93%, and 80% respectively 4. Start at 25 mg once daily for all Child-Pugh classes (A, B, C) in ITP and aplastic anemia 1.

Critical exception: For chronic hepatitis C patients, no dose adjustment is recommended despite underlying liver disease 1. This reflects the different risk-benefit profile in this population where thrombocytopenia management enables life-saving antiviral therapy.

Renal Impairment

No dose adjustment required for any degree of renal impairment 4. Pharmacokinetic data showed mean AUC decreases of 32%, 36%, and 60% in mild, moderate, and severe renal impairment respectively 4. Patients should initiate at standard 50 mg daily with close monitoring 4.

Administration Requirements

Timing relative to food and medications is critical for absorption:

• Take without food or with a low-calcium meal (≤50 mg calcium) 1
• Separate from polyvalent cations by:
  • At least 2 hours before antacids, calcium-rich foods, or mineral supplements
  • At least 4 hours after these products 1

This separation is essential because eltrombopag chelates with metal cations (calcium, aluminum, magnesium, iron, zinc), dramatically reducing absorption 1.

Tapering and Discontinuation

The 2020 expert panel recommendations provide the most detailed tapering guidance 2:

Eligibility criteria for tapering:

• Stable platelet count ≥50 × 10⁹/L (partial response) or ≥100 × 10⁹/L (complete response) 2
• Response maintained ≥6 months without concomitant treatments 2
• No hemorrhagic events during this period 2

Tapering schedule:

1. Reduce by 25 mg every 2 weeks until reaching 25 mg daily 2
2. Then switch to 25 mg every other day for 2 weeks 2
3. Then 25 mg every 4 days before discontinuation 2

For suboptimal responders: Slower tapering over 6-12 months may be appropriate 2

Monitor closely: Approximately 40% of patients undergo successful tapering, with 18% achieving sustained remission off therapy 2. Complete response at low doses is a positive prognostic factor for durable remission 2.

Monitoring Requirements

Hepatotoxicity surveillance is mandatory given boxed warnings 1:

• Baseline: Liver function tests before initiation 1
• During therapy: Monitor ALT, AST, and bilirubin regularly 1
• Discontinue if: ALT increases to ≥3× ULN in patients with normal baseline or worsens in those with elevated baseline 1

Platelet monitoring:

• Weekly until stable platelet count achieved 1
• Then monthly thereafter 1
• More frequently during dose adjustments 1

Special Populations

Pregnancy: No adequate human data; use only if benefit outweighs risk 1

Lactation: Breastfeeding not recommended during treatment due to potential serious adverse reactions 1

Pediatric <6 years with ITP: Safety and effectiveness not established 1

Geriatric: No dose adjustment needed; 22% of ITP trial participants were ≥65 years 1

Common Pitfalls

1. Failing to separate from calcium/antacids: This is the most common cause of treatment failure due to chelation reducing absorption to negligible levels
2. Not reducing dose for hepatic impairment in ITP/aplastic anemia: The 93% increase in exposure with moderate hepatic impairment substantially increases hepatotoxicity risk
3. Applying hepatic dose reduction to hepatitis C patients: These patients should receive standard dosing per FDA label
4. Exceeding maximum doses: 75 mg/day for ITP, 150 mg/day for aplastic anemia 1
5. Rapid tapering: The expert panel emphasizes slow, structured tapering over 2-week intervals to maximize sustained remission rates 2

Role in Treatment Algorithm

The 2019 ASH guidelines position eltrombopag as second-line therapy for ITP 5. For adults with ITP ≥3 months who are corticosteroid-dependent or unresponsive, thrombopoietin receptor agonists are recommended for patients at bleeding risk who have failed at least one other therapy (grade 1B) 6. The guidelines suggest either eltrombopag or romiplostim, with choice based on patient preference for oral versus subcutaneous administration 5.

For pediatric ITP, current guidelines recommend eltrombopag as the drug of choice for second-line therapy 7. Recent real-world data show 94% of pediatric patients achieved successful dose de-escalation, with 15% achieving full discontinuation 7.